Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 280, Issue 35, Pages 31109-31115Publisher
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M505402200
Keywords
-
Categories
Funding
- NCI NIH HHS [CA81436] Funding Source: Medline
Ask authors/readers for more resources
Atypical protein kinase C ( aPKC) isozymes function in epithelial cell polarity, proliferation, and survival and have been implicated in cellular transformation. However, the role of these enzymes in human cancer is largely unexplored. Here, we report that aPKC iota is highly expressed in human non-small cell lung cancer cell lines, whereas the closely related aPKC isozyme PKC iota is undetectable in these cells. Disruption of PKC iota signaling reveals that PKC iota is dispensable for adherent growth of non-small cell lung cancer cells but is required for transformed growth in soft agar in vitro and for tumorigenicity in vivo. Molecular dissection of signaling downstream of PKC iota demonstrates that Rac1 is a critical molecular target for PKC iota-dependent transformation, whereas PKC iota is not necessary for NF kappa B activation in vitro or in vivo. Expression of the PB1 domain of PKC iota (PKC iota- (1-113)) blocks PKC iota-dependent Rac1 activity and inhibits cellular transformation indicating a role for this domain in the transforming activity of PKC iota. Taken together, our data demonstrate that PKC iota is a critical lung cancer gene that activates a Rac1 -> Pak -> Mek1,2 -> Erk1,2 signaling pathway required for transformed growth. Our data indicate that PKC iota may be an attractive molecular target for mechanism-based therapies for treatment of lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available